Omeros Corporation (OMER)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 8.98 |
Market Cap | 521.84M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -3.14 |
PE Ratio (ttm) | -2.87 |
Forward PE | n/a |
Analyst | Hold |
Ask | 9.03 |
Volume | 82,774 |
Avg. Volume (20D) | 1,122,955 |
Open | 9.26 |
Previous Close | 9.19 |
Day's Range | 8.97 - 9.29 |
52-Week Range | 2.61 - 13.60 |
Beta | undefined |
About OMER
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell tr...
Analyst Forecast
According to 4 analyst ratings, the average rating for OMER stock is "Hold." The 12-month stock price forecast is $22.5, which is an increase of 149.86% from the latest price.
Why Price Moved
News

2 months ago · businesswire.com
Omeros Corporation Announces Upcoming Presentations at ASH Annual MeetingSEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that two abstracts directed to zaltenibart (OMS906), Omeros' investigational inhibitor of MASP-3, the key activator of the a...

2 months ago · businesswire.com
Omeros Corporation Provides Update on Progress Toward BLA ResubmissionSEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced an update on its progress toward planned resubmission of its biologics license application (“BLA”) for narsoplimab, the comp...

2 months ago · businesswire.com
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2024, on Wednesday, November 13, 2024...